Stockscreener 앱 받기
1.42
5.96%
-0.09
시장 영업 전:
1.47
0.05
+3.52%
전일 마감가:
$1.51
열려 있는:
$1.48
하루 거래량:
508.24K
Relative Volume:
0.73
시가총액:
$161.08M
수익:
$42.51M
순이익/손실:
$-116.49M
주가수익비율:
-1.2679
EPS:
-1.12
순현금흐름:
$-120.82M
1주 성능:
-4.70%
1개월 성능:
+11.81%
6개월 성능:
-72.59%
1년 성능:
-81.34%
1일 변동 폭
$1.38
$1.51
1주일 범위
$1.26
$1.56
52주 변동 폭
$1.11
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
TNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
1.42 | 161.08M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study - Barchart.com
There is no way Tango Therapeutics Inc (TNGX) can keep these numbers up - Sete News
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewswire
Is Tango Therapeutics Inc (TNGX) worth investing in despite its undervalued state? - uspostnews.com
Tango Therapeutics Inc (TNGX) Stock: A Year of Highs and Lows - investchronicle.com
Insider’s View: Deciphering Tango Therapeutics Inc (TNGX)’s Financial Health Through Ratios - DWinneX
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Geode Capital Management LLC - Defense World
Now Is The Time To Build A Position In Tango Therapeutics Inc (NASDAQ:TNGX) - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX
What is the investor’s view on Tango Therapeutics Inc (TNGX)? - uspostnews.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Franklin Resources Inc. - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.33 Average PT from Analysts - Defense World
Equities Analysts Offer Predictions for TNGX Q1 Earnings - Defense World
Tango Bypasses IPO Route With SPAC Merger - insights.citeline.com
What is HC Wainwright’s Estimate for TNGX Q1 Earnings? - Defense World
Tango Therapeutics’ (TNGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright - Investing.com Canada
Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding - simplywall.st
American Century Companies Inc. Purchases 12,162 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Barbara Weber, M.D., Elected to ITM Supervisory Board - Yahoo
Reviewing Biomea Fusion (NASDAQ:BMEA) and Tango Therapeutics (NASDAQ:TNGX) - Defense World
Tango Therapeutics cuts nearly one-fifth of staff - BioPharma Dive
TNGX’s Wild Ride: Down -55.66% – What’s Next for TNGX? - investchronicle.com
How Will Tango Therapeutics Inc (NASDAQ: TNGX) Perform In Months To Come? - Marketing Sentinel
Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Charles Schwab Investment Management Inc. Acquires 26,192 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Bank of New York Mellon Corp Sells 8,715 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics to Highlight Preclinical Data on - GlobeNewswire
Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors - Stock Titan
Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa
Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials - Investing.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 18.5% in February - Defense World
Tango Therapeutics executive sells shares worth $43,865 - MSN
Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World
Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN
Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St
Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK
Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks
Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Tango Therapeutics, Inc. SEC 10-K Report - TradingView
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):